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ABSTRACT
Due to the severity of chronic hepatitis C, there are multiple factors that can negatively 
affect the quality of life of infected patients. The aim of this study was to evaluate changes in 
the health-related quality of life (HRQoL) in patients under second-generation direct-acting 
antiviral (DAA) (interferon-free) therapies and to assess treatment effectiveness. This was 
an observational study conducted in Curitiba (Brazil) using two instruments (a generic and 
a specific) for measuring the quality of life in patients with chronic hepatitis C, the Short 
Form-36 (SF-36) and the Chronic Liver Disease Questionnaire (CLDQ) for liver disease 
evaluation. The study included patients receiving any interferon-free therapy for hepatitis 
C treatment during 2016 and 2017. Data were collected before, during, and after treatment 
regarding the two questionnaires, effectiveness and safety. Fifty-six patients fulfilled all 
eligibility criteria and were included for analysis. Sustained virological response was obtained 
in 88% of the patients. They were mainly genotype 1, cirrhotic and treated with sofosbuvir 
combined with daclatasvir or sofosbuvir with simeprevir. Improvement in the quality of 
life was observed for several domains in both questionnaires (p < 0.05) in the comparison 
before and after treatment. Patients receiving sofosbuvir with daclatasvir had significantly 
lower scores compared to the group receiving sofosbuvir with simeprevir. Second-generation 
DAA therapies were effective and have considerably increased the HRQoL of patients with 
chronic hepatitis C virus.
KEYWORDS: Health-related quality of life. Hepatitis C. Interferon-free. SF-36. Chronic 
Liver Disease Questionnaire. CLDQ.
INTRODUCTION
Patients’ emotional, social and physical well-being have been increasingly 
investigated and recognized as an important outcome, particularly in developed 
countries presenting a high prevalence of chronic diseases. The measurement of these 
subjective parameters is translated by the health-related quality of life (HRQoL), 
which quantifies the impact of a disease and its treatment on the individual1,2.
Standing out among widely investigated chronic diseases is hepatitis C, an 
infectious condition that affects 71 million people worldwide3. In Brazil, a low-
income country, it is estimated that the chronic infection by hepatitis C virus (HCV) 
affects more than 2 million people4. 
Considering the severity of chronic hepatitis C, recognized as a major public 
health issue, its proper management is paramount for controlling infection 
dissemination, especially due to its slow progression and high number of chronic 
cases, making early diagnosis difficult. This fact postpones the beginning of 
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treatment, which is decisive for stopping the progression 
of the disease. Hence, several treatment options have 
emerged in recent years, highlighting direct-acting antivirals 
(DAAs)5. Since the approval of the first-generation DAAs 
by the Food and Drug Administration (FDA) in 2011, 
treatment regimens have undergone numerous changes. 
The latest therapies (since 2014) include interferon-free 
schemes, more effective in terms of sustained virological 
response (SVR) and associated with less adverse events 
when compared to previous regimens6,7. The new wave of 
therapies with interferon-free schemes was incorporated 
into the Brazilian guidelines for chronic hepatitis C 
treatment in 20154.
In terms of quality of life, since chronic hepatitis C 
may promote extra-hepatic manifestations (e.g. depression, 
cognitive deficit, and arthralgia) even in the absence of 
hepatic impairment, HRQoL has a negative impact on both, 
physical and mental aspects. As a consequence, patients 
may present productivity and work capacity loss, in addition 
to difficulties in the execution of other daily activities. This 
scenario imposes a significant socio-economic burden on 
patients and their relatives, as well as on the health system. 
Therefore, the assessment of patients’ quality of life is 
highly relevant8-11. In this sense, several instruments are 
available to measure HRQoL in this population. The most 
commonly used questionnaires are the Medical Outcomes 
Study 36-item Short-Form Health Survey (SF-36) and the 
EuroQoL-EQ-5D, which are both generic, and the Chronic 
Liver Disease Questionnaire (CLDQ), which is specific for 
liver diseases12-14.
Since chronic hepatitis C treatment guidelines have 
been recently updated in Brazil15 and considering the lack 
of data regarding the quality of life of patients treated in 
public health institutions in the country, this study aimed to 
evaluate changes in the HRQoL in patients under interferon-
free therapies and to assess treatment effectiveness. 
MATERIAL AND METHODS
Study design and participants
This is a prospective observational study carried out in 
the Pharmacy of Specialized Component of Pharmaceutical 
Assistance in the city of Curitiba, South Brazil. It was 
conducted between 2016 and 2017. All patients diagnosed 
with HCV infection who were over 18 years of age 
and eligible for treatment with interferon-free regimens 
were invited to participate in the study, including those 
co-infected with hepatitis B virus (HBV) and with human 
immunodeficiency virus (HIV). Inclusion criteria also 
followed the recommendations of the 2015 Brazilian 
guidelines4. Patients with incapacitating extra-hepatic 
neurological manifestations, with any condition that prevented 
the understanding and completion of the questionnaires, who 
were lost to follow-up after the end of treatment, who did not 
complete the questionnaires (more than three unanswered 
questions), or who had the questionnaires answered by third 
parties were excluded from the study. 
Treatment regimens 
We evaluated the treatment regimens with DAAs 
approved by the Brazilian Ministry of Health and provided 
by the public health system according to the 2015 Brazilian 
guidelines for chronic hepatitis C treatment. Therapeutic 
regimens included sofosbuvir (SOF) 400 mg PO q/day, 
daclatasvir (DAC) 60 mg PO q/day, simeprevir (SMV) 
150 mg PO q/day, and ribavirin (RBV) 250 mg (11 mg/kg/day 
PO or 1 g PO [< 75 kg] or 1.2 g PO [> 75 kg]). 
Data collection
After identifying eligible patients and obtaining the 
signed informed consent, we collected baseline and disease 
history data of the participants. Baseline data included age, 
time of diagnosis, history of alcoholism and/or injecting 
drugs, other comorbidities, ethnicity, marital status, sex, 
and schooling. The history related to the disease comprised 
previous treatments and respective responses, assessment of 
hepatic impairment, stage of liver fibrosis and/or presence 
of cirrhosis, presence of extra-hepatic manifestations, virus 
genotype, quantitative viral load (HCV-RNA), and HIV 
coinfection.
For a comprehensive assessment of patients’ HRQoL, 
the SF-36 and CLDQ were applied before starting and after 
the end of treatment. The SF-36 is the most widely used 
generic instrument. It is a multidimensional questionnaire 
consisting of 36 items and is divided into eight domains: 
physical functioning (PF), role limitation due to physical 
health (PH), pain (P), general health (GH), vitality (V), 
social functioning (SF), emotional well-being (EW) and 
mental health (MH). Results are expressed as a score 
ranging from 0 to 100 for each of the eight scales, with 
higher scores indicating a better quality of life16,17. 
The CLDQ, a specific instrument, is composed of 29 
questions distributed in six domains, including abdominal 
symptoms (AS), fatigue (FA), systemic symptoms (SS), 
activity (AT), emotional function (EF), and worry (WO). 
Scores range from 1 (worst) to 7 (least severe), in which 
higher scores indicate a minimum frequency of symptoms 
and, consequently, a better quality of life. An overall score 
is calculated by averaging the six dimensions14,18,19.
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In addition, information on adverse events and 
treatment discontinuation were collected. Data on treatment 
effectiveness were assessed by SVR rates 12 or 24 weeks 
after treatment completion. Patients were followed up until 
six months after the end of treatment. All data collected were 
documented in a clinical record designed specifically for 
the study and then compiled in an Excel spreadsheet using 
the software Microsoft Office Excel® 2013. 
Ethical aspects
The present study was conducted according to the 
Declaration of Helsinki and the Resolution 466/2012 of the 
Brazilian National Health Council. The Ethics Committee 
on Human Research of the Universidade Federal do Parana 
and the Ethics Committee of the State Secretary of Health 
(Curitiba, Parana, Brazil) approved the study protocol 
(Nº 68049517.9.3001.5225). We received authorization to 
conduct the study in the pharmacy of the Second Regional 
Health by the direct coordination and by the Department 
of Pharmaceutical Assistance of the Parana State. All 
participants provided written informed consents. 
Statistical analysis
Data recorded in Microsoft Office Excel® 2013 were 
processed according to each applied instrument and then 
transferred to the software IBM® SPSS® Statistics version 20 
(Armonk, NY: IBM Corp.), in which all statistical analyses 
were performed. Qualitative variables were expressed as 
absolute and relative frequencies, and quantitative variables 
were presented as means and standard deviations (SD). 
The Kolmogorov-Smirnov test was used to verify the 
distribution of parameters. As data distribution was not 
normal, non-parametric tests were applied in the comparative 
analysis. For statistical analysis of the HRQoL instruments, 
we applied the non-parametric test for Wilcoxon-related 
samples, in which domains were evaluated in pairs, with 
values referring to before and after treatment, for each 
instrument. This test allowed the comparison of HRQoL 
within a single group of patients. The analysis to compare 
quality of life in patients receiving different treatments 
was performed using the Mann-Whitney U test. For all 
analyses, the significance level of p <0.05 was adopted, 
with a confidence level of 95%.
RESULTS
Baseline characteristics
In the period in which the study was conducted, 
324 patients started DAA treatment and were invited to 
participate in the research, but only 112 accepted. Finally, 56 
patients fulfilled all eligibility criteria and were included for 
analysis. All baseline characteristics and socio-demographic 
data are presented in Table 1.
Table 1 - Socio-demographic and clinical variables of the study 
population
Parameter Total patients (n=56)
Gender, n (%)
Male 37 (66%)
Female 19 (34%)
Mean age (SD) years 57.4 ± 11.4
Treatment received
SOF + DAC ± RBV 38 (67.8%)
SOF + SMV ± RBV 17 (30.3%)
SOF + RBV 1 (1.7%)
Time since diagnosis, years (SD) 10.87 ± 9.67
Genotype 
1 42 (75%)
2 1 (1.7%)
3 13 (23.2%)
Treatment duration
12 w 44 (78.5%)
24 w 12 (21.5%)
Metavir
NI 15 (26.7%)
F2 9 (16%)
F3 15 (26.7%)
F4 17 (30.3%)
Patients previously treated 35 (62%)
Viral load ≥ 800.000 IU mL-1 27 (48%)
Race
White 41 (73.2%)
Black 5 (9%)
Others 10 (17%)
Marital status
Married 31 (55%)
Single 10 (17.8%)
Separated 10 (17.8%)
Widowed 5 (9%)
Educational level
Illiterate 1 (1.7%)
Elementary school 8 (14.2%)
Secondary school 29 (51%)
High school 18 (32%)
Patients with other comorbidities 33 (59%)
Patients with addictions 16 (28%)
Abbreviations: NI: not informed; RBV: ribavirin; SOF: sofosbuvir; 
SMV: simeprevir
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Evaluation of the quality of life
The HRQoL of hepatitis C patients was improved 
after the use of second-generation DAAs. The evaluation 
of HRQoL before and after treatment through SF-36 and 
CLDQ showed an improvement in different domains 
(Table 2). In the case of SF-36, a statistical difference was 
observed (p<0.05) - i.e., an increase in patients’ HRQoL 
- in six of the eight domains: PF, PH, P, GH, V, and MH. 
Patients have also presented significantly higher averages 
after treatment (p<0.05) in four of the six domains in the 
CLDQ: EF, WO, SS and overall score. 
To compare the quality of life in patients receiving 
different treatments (SOF + DAC versus SOF + SMV, both 
with or without RBV) another analysis was performed. 
We observed that patients receiving SOF + DAC ± RBV 
had significantly lower scores before and after treatment 
compared to the ones receiving SOF + SMV (Table 3). 
Outcomes regarding treatment effectiveness and 
safety
Data of two patients were not available for effectiveness 
outcomes (missing data); therefore, they were excluded 
from this analysis. SVR was obtained in 48 of 54 patients 
(88.8%). Regarding treatment, 32 of 36 patients who 
received SOF + DAC ± RBV and 16 of 17 patients who 
received SOF + SMV ± RBV achieved SVR (88.8% and 
94.1%, respectively). The only patient who was treated with 
SOF + RBV was cured.
Only five of the 56 patients (8.9%) who were evaluated 
for safety outcomes did not present any adverse events. 
Among the most commonly reported adverse events during 
treatment, the following stand out: headache (57%), fatigue 
(46%), muscle pain (32%), sleep problems (35%), itching 
(30%), nausea (26%), dizziness (21%) and diarrhea (14%). 
No patients discontinued treatment due to adverse events.
DISCUSSION
The present study evaluated the use of antiviral 
treatment and changes in the quality of life in patients 
infected with HCV. 
A previous study conducted in Brazil compared the 
quality of life of chronic hepatitis C patients receiving 
antiviral interferon-based therapies, including interferon 
and RBV, in some cases combined with first-generation 
DAAs boceprevir and telaprevir20. Besides the clinical 
conditions of those patients, HRQoL was affected 
by treatment complications, which were associated 
with a significant number of side effects, low efficacy, 
treatment discontinuations and the requirement of frequent 
injections21-23. 
In the present study, most patients received SOF + 
DAC + RBV (67.8%), which is explained by the baseline 
characteristics of evaluated individuals. This treatment 
Table 2 - Comparison of SF-36 and CLDQ scores between patients before and after treatment
Domains of SF-36 and CLDQ Before treatment After treatment p-value
SF-36
PF 56 (±66.4) 71.7 (±28.7) 0.043*
PH 44.6 (±43.6) 60.7 (±43.9) 0.014*
P 52.8 (±25.9) 62.7 (±25) 0.006*
GH 54.11 (±24.7) 62.9 (±24.8) 0.002*
V 50.4 (±26.8) 60 (±28) 0.007*
SF 64.2 (±30.7) 71.2 (±32.1) 0.076
EW 46.4 (±45.6) 55.3 (±46.3) 0.096
MH 59.9 (±24.5) 67.1 (±22.1) 0.006*
CLDQ
AS 4.04 (±1.78) 4.14 (±1.74) 0.803
FA 3.35 (±1.65) 3.75 (±1.64) 0.083
AT 4.26 (±1.7) 4.32 (±1.65) 0.507
EF 3.55 (±1.62) 4.01 (±1.44) 0.007*
WO 3.58 (±1.65) 4.85 (±1.31) 0.001*
SS 4.05 (±1.33) 4.42 (±1.14) 0.033*
Overall score 3.81 (±1.31) 4.25 (±1,13) 0.003*
Note: *p<0.05. Abbreviations: AS: abdominal symptoms; AT: activity; EW: emotional well-being; EF: emotional function; FA: fatigue; 
GH: general health; MH: mental health; P: pain; PF: physical functioning; PH: role limitations due to physical health; SF: social 
functioning; SS: systemic symptoms; V: vitality; WO: worry
Rev Inst Med Trop São Paulo. 2018;60:e72
Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies
Page 5 of 7
regimen is indicated for patients with more advanced 
disease, treatment-experienced, or patients coinfected with 
HIV, conditions presented by a high number of patients in 
this cohort. 
The results of this study are clear, in the sense that 
even with the presence of some adverse events, HRQoL of 
HCV patients had increased after treatment with second-
generation DAAs. This can be explained by the fact that 
many patients had been cured with interferon-free therapies, 
which are given orally, and they have also had lower severity 
of adverse events, which raises the perception of quality of 
life of these patients24-26. Additionally, SVR rates obtained 
in our study were similar to previous studies results27,28. 
We observed that the patients treated with SOF + SMV 
had a higher HRQoL compared to those patients receiving 
SOF + DAC. This could be explained by the fact that 
the latter treatment is recommended for patients in a 
more advanced stage of the disease and in more complex 
situations, including patients with genotype 3 virus, which 
is known as the most difficult to treat27-29.
We did not conduct an analysis on the influence of 
comorbidities and patient’s addictions (e.g. alcoholism and 
illicit drug use). However, these conditions are expected to 
affect the patient’s perceptions regarding its quality of life. A 
strong association of intravenous drug use with depression 
as well as of alcoholism with disease progression, and 
HIV coinfection with fatigue resulting in impairment of 
psychological, physical and social HRQL domains11,30,31. 
According to the latest Brazilian guideline, updated in 2018, 
treatment for chronic hepatitis C comprises regimens with 
the following DAAs: daclatasvir; simeprevir, sofosbuvir, 
ombitasvir, dasabuvir, veruprevir, ritonavir, ledipasvir, 
elbasvir and grazoprevir. The aforementioned treatments 
are now available through the public health system to all 
patients diagnosed with HCV infection, regardless of the 
liver fibrosis stage15.
This study was carried out in 2016 and 2017 so that we 
followed up patients receiving the therapies encompassed 
in the 2015 guideline, which was a limitation of the study. 
Nevertheless, as the evaluated regimens are also included 
in the updated version of treatment protocols, the results 
addressed herein are useful for guiding clinicians in 
the decision-making process in order to ensure the best 
treatment option according to the patient profile and 
effectiveness of treatment regimen.
CONCLUSION
Second-generation DAA therapies were effective and 
safe for the treatment of chronic hepatitis C patients. In 
line with these previous results, there was a substantial 
increase of HRQoL in patients treated with SOF + DAC 
Table 3 - Comparison of SF-36 and CLDQ scores between SOF + DAC versus SOF + SMV patients before and after treatment.
Domains of SF-36 and CLDQ
Before treat-
ment with SOF 
+ DAC ± RBV
Before treat-
ment with SOF 
+ SMV ± RBV
p-value
After treatment 
with SOF + 
DAC ± RBV
After treatment 
with SOF + 
SMV ± RBV
p-value
SF-36 PF 63.9 (±30.8) 70.2 (±30.8) 0.493 69.3 (±29.0) 75.5 (±28.5) 0.420
PH 40.1 (±42.9) 57.3 (±43.9) 0.217 51.9 (±44.0) 77.9 (±39.4) 0.045*
P 50.5(±25.1) 61.2 (±24.4) 0.228 57.8 (±24.9) 72.0 (±22.9) 0.040*
GH 49.4 (±25.8) 62.2 (±18.4) 0.083 59.1 (±26.1) 69.6 (±19.4) 0.179
V 45.7 (±27.7) 57.9 (±21.0) 0.123 54.4 (±27.7) 70 (±25.1) 0.043*
SF 56.2 (±32.0) 83.8 (±16.3) 0.003* 64.8 (±32.2) 83.8 (±28.9) 0.014*
EW 37.7 (±43.9) 68.6 (±43.2) 0.026* 42.1 (±46.2) 82.3 (±33.5) 0.006*
MH 52.8 (±25.0) 73.6 (±14.9) 0.003* 62 (±22.3) 77.1 (±17.8) 0.016*
CLDQ AS 3.9 (±1.8) 4.1 (±1.7) 0.862 4.1 (±1.7) 4.1 (±1.8) 0.956
FA 3.0 (±1.6) 3.9 (±1.4) 0.060 3.5 (±1.6) 4.2 (±1.5) 0.141
AT 4.0 (±1.6) 4.7 (±1.7) 0.035* 4.2 (±1.5) 4.3 (±1.9) 0.605
EF 3.1 (±1.6) 4.3 (±1.2) 0.017* 3.7 (±1.4) 4.5 (±1.2) 0.051
WO 3.3 (±1.7) 4.0 (±1.3) 0.205 4.6 (±1.4) 5.3 (±1.0) 0.031*
SS 3.9 (±1.3) 4.2 (±1.3) 0.629 4.2 (±1.1) 4.8 (±1.1) 0.040*
Overall score 3.5 (±1.3) 4.2 (±1.1) 0.087 4.0 (±1.1) 4.5 (±0.9) 0.236
Note: *p<0.05. Abbreviations: AS: abdominal symptoms; AT: activity; EW: emotional well-being; EF: emotional function; FA: fatigue; 
GH: general health; MH: mental health; P: pain; PF: physical functioning; PH: role limitations due to physical health; SF: social 
functioning; SS: systemic symptoms; V: vitality; WO: worry
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or SOF + SMV with or without RBV, detected by the 
various domains of the SF-36 and CLDQ. Further studies 
evaluating the quality of life of patients using the other 
therapies included in the latest guideline should be 
conducted.
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